Please login to the form below
Batten disease
This page shows the latest Batten disease news and features for those working in and with pharma, biotech and healthcare.
NICE approves BioMarin’s Brineura after initial setback
First treatment for rare disease. BioMarin and NICE had a rocky start with Batten disease therapy Brineura, but the two have now come to an agreement. ... The disease, known as neuronal ceroid lipfuscinosis type 2 (CLN2), is a very rare inherited
Latest news
-
BioMarin ticks over in Q2 ahead of gene therapy filing
A second-generation treatment for rare disease phenylketonuria (PKU), the newly launched drug reported $18.8m in sales. ... BioMarin will also hope to extend the commercial success of Brineura, its Batten disease therapy.
-
Amicus forms gene therapy manufacturing partnership with Catalent
Amicus has one rare disease medicine already on the market, Galafold for Fabry disease, with an enzyme replacement therapy (AT-GAA) for Pompe disease in its late stage pipeline, to which ... capabilities. Thermo Fisher will supply Amicus with immediate
-
NICE knocks back BioMarin’s Batten disease drug
The committee initially agreed that Brineura shows substantial short-term benefits in slowing down the rate of Batten disease progression in draft guidance, but said BioMarin was unable to price the ... Results from a phase 1 and 2 clinical trial show
-
CHMP backs two rare disease therapies at April meeting
BioMarin got a green light for Brineura (cerliponase alfa), an enzyme replacement therapy for the ultra-rare neurodegenerative disease neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease that ... There is no approved drug to treat the
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
How understanding the rare disease patient’s lived experience creates better health communications
Children like Noah Van Houtan, and his sister Laine – who both had CLN2 Batten Disease. ... With the co-operation of the VanHoutan family, the film describes their journey with CLN2 Batten Disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Bedrock mark International Batten Disease Awareness Day 2022 with Noah's Story
Batten Disease is a group of fatal genetic disorders. There are 13 types. ... Hope4Bridget and the story that the VanHoutan’s share about their family’s journey with CLN2 Batten Disease.
-
Shining a light on rare diseases with ‘Noah’s Story’
In recognition of Rare Disease Day, Bedrock share 4 minutes of a true story you won’t want to miss. ... Sadly about 75% of rare diseases affect children like Noah who had CLN2 Batten Disease, and one in three children with a rare disease won’t live
-
Bedrock to raise awareness of Rare Disease Day 2022 with film 'Noah's Story'
Children like Noah – who had CLN2 Batten Disease. The film will premiere on Rare Disease Day, Monday February 28th. ... Hope4Bridget and the story that the VanHoutan’s share about their family’s journey with CLN2 Batten Disease.
-
Bedrock Healthcare Communications
App development. Congress and symposia. Content strategy and execution. Disease awareness campaign and fulfilment. ... Bedrock to raise awareness of Rare Disease Day 2022 with film 'Noah's Story'.
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
